IRVINE, Kalifornien, Aug. 18, 2025 (GLOBE NEWSWIRE) — Read more »
Solução Lantronix Capacita a Teal Drones, uma empresa da Red Cat Holdings Co. Aprovada pelo Exército dos EUA, Desbloqueando uma Oportunidade de Crescimento da Edge AI Segura
IRVINE, Califórnia, Aug. 18, 2025 (GLOBE NEWSWIRE) — A Read more »
Lantronix Solution Powers U.S. Army-Approved Teal Drones, a Red Cat Holdings Co., Unlocking Secure Edge AI Growth Opportunity
IRVINE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) — Read more »
Teal Drones, fabricant de drones approuvés par l’armée américaine et filiale de Red Cat Holdings, adopte la solution Lantronix, ouvrant ainsi de nouvelles perspectives de croissance pour l’IA sécurisée en périphérie de réseau
IRVINE, Californie, 18 août 2025 (GLOBE NEWSWIRE) — Read more »
WeRide Secures Strategic Equity Investment from Grab, Partners to Deploy Robotaxis and Autonomous Shuttles in Southeast Asia
NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) — WeRide (NASDAQ: WRD), a global leader in autonomous driving technology, announced today that Grab (NASDAQ: GRAB), Southeast Asia’s leading superapp, has [...] Read more »
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
Mont–Saint–Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA [...] Read more »
Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025
Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025
Mont–Saint–Guibert, Belgique – 11 [...] Read more »
Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l'Apnée Obstructive du Sommeil
INFORMATIONS PRIVILÉGIÉES
INFORMATIONS RÉGLEMENTÉES
Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® [...] Read more »
Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea
INSIDE INFORMATION
REGULATED INFORMATION
Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea
Read more »
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
- FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density [...] Read more »